Mybacs wins an international investor

Founded by Sebastian Wahl and Carl-Philipp von Polheim, Mybacs aims to revolutionize the healthcare sector around the human microbiome. With their formulation of specially selected bacteria cultures (probiotics), prebiotics as well as minerals and vitamins, the company focuses on synbiotic dietary supplements, which are tailored to the individual needs and areas of application of its customers.

In 2018, mybacs had a successful market entry with the launch of its travel product Travelbacs - a regionally tailored bacterial composition to prepare the digestion for specific travel regions. After a successful first round of financing in August 2019, the company has since been able to expand its team and marketing activities further. With Dailybacs, the company has furthermore expanded its product portfolio by also providing a synbiotic for daily use, available on a subscription basis, which is tailored to the needs of women, men and children.

The company has been able to convince existing and new investors to contribute to its Seed II round. Alongside Global Founders Capital (GFC, one of the most successful Venture Capital firms in the B2C sector founded by Oliver Samwer) are business angels that are once again investing in the company and Joyance Partners, which joined as the first international investor in the round. The obtained funds will enable the company to grow its team to develop personalized products and a dedicated tech platform. The new investment will flow into further expansion of the team for developing personalized products and the development of a dedicated tech platform

“We are very pleased about the new round of financing and highly appreciate the trust our investors have placed in us,” says Carl-Philipp von Polheim, founder and Co-CEO of mybacs. “Our customers’ positive feedback and the accompanying growth since the launch of our Dailybacs once again confirms that there is a great demand for products related to intestinal health and the human microbiome. This is where we want to focus on with the new investment sum by developing further products to be able to respond even more specifically to the individual needs of our customers. Accordingly, we will expand our team to include specialists in the fields of technology and data, and will continue to drive forward the personalization of our products with the help of a platform for symptomatic and intelligent data analysis”.

(Press release/RAN)